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Abstract
Background: In a previous study, we observed that oxidized low-density lipoprotein-induced
death of endothelial cells was calpain-1-dependent. The purpose of the present paper was to study
the possible activation of calpain in human carotid plaques, and to compare calpain activity in the
plaques from symptomatic patients with those obtained from patients without symptoms.
Methods: Human atherosclerotic carotid plaques (n = 29, 12 associated with symptoms) were
removed by endarterectomy. Calpain activity and apoptosis were detected by performing
immunohistochemical analysis and TUNEL assay on human carotid plaque sections. An antibody
specific for calpain-proteolyzed α-fodrin was used on western blots.
Results: We found that calpain was activated in all the plaques and calpain activity colocalized with
apoptotic cell death. Our observation of autoproteolytic cleavage of the 80 kDa subunit of calpain-
1 provided further evidence for enzyme activity in the plaque samples. When calpain activity was
quantified, we found that plaques from symptomatic patients displayed significantly lower calpain
activity compared with asymptomatic plaques.
Conclusion: These novel results suggest that calpain-1 is commonly active in carotid artery
atherosclerotic plaques, and that calpain activity is colocalized with cell death and inversely
associated with symptoms.
Background
Calpains are calcium-dependent cysteine proteases that
are known to be involved in the proteolysis of a number
of proteins during mitosis and cell death [1,2]. The cal-
pains constitute a large family of distinct isozymes that
differ in structure and distribution [3], and three members
of this family are ubiquitous – calpain-1 (μ-calpain), cal-
pain-2 (m-calpain), and calpain-10. A study with embry-
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onic fibroblasts from mice with genetically disrupted
capn4, which codes for the regulatory subunit of both cal-
pain-1 and -2, showed that calpains are required for acti-
vation of caspase-12 and c-Jun N-terminal kinase in ER-
stress-induced apoptosis [4]. The specific endogenous
protein inhibitor calpastatin, which modulates calpain
activity  in vivo, is cleaved during apoptosis [5]. The
cytoskeletal protein α-fodrin is another death substrate
that may be cleaved by calpains or caspases [1,6]. Addi-
tional calpain substrates known to be involved in apopto-
sis are Bax [7], Bid [8], p53 [9], and procaspase-3, -7, -8,
and -9 [10,11]. In a previous study, we found that oxi-
dized low-density lipoprotein (oxLDL)-induced death of
human microvascular endothelial cells (HMEC-1) was
accompanied by activation of calpain-1 [12]. The calpain-
1 inhibitor, PD 151746, decreased oxLDL-induced cyto-
toxicity, and the 80 kDa subunit of calpain-1 was autopro-
teolytically cleaved in oxLDL-treated HMEC-1 cells,
indicating that the enzyme was activated. The Bcl-2 pro-
tein Bid was also cleaved during oxLDL-elicited cell death,
and this was prevented by calpain inhibitors, but not by
inhibitors of cathepsin B or caspases.
Vascular calcification is present in 80% of significant
atherosclerotic lesions and in at least 90% of patients with
coronary artery disease [13]. Calcification can apparently
begin at any point of plaque formation and seems to be a
complex mechanism [14]. Since vascular calcification has
been shown to correlate with elevated serum calcium
[15], and oxLDL plays a central role in atherogenesis [16],
we hypothesized that calpains may be activated in athero-
sclerotic lesions. Therefore, the primary aim of the present
study was to analyze atherosclerotic plaques for possible
calpain activity.
Methods
Materials
Anti-calpain-1 large subunit monoclonal Ab was from
Chemicon International (Temecula, CA, MAB3082), anti-
α-tubulin monoclonal Ab was from Oncogene Research
Products (Boston, MA, #CP06). HRP-coupled goat anti-
rabbit and goat anti-mouse immunoglobulins were from
Dako A/S (Glostrup, Denmark). Reagents not listed here
were obtained from Sigma, unless otherwise stated in the
text.
Atherosclerotic plaques
Twenty-nine human atherosclerotic carotid plaques, from
26 patients (67 ± 8 years old, 21 males), were removed en
bloc by carotid endarterectomy by one surgeon. Twelve
plaques were associated with ipsilateral hemispheric
symptoms in the last month and 17 were not associated
to any symptoms after neurologic evaluation. Cardiovas-
cular risk factors such as hypertension (systolic blood
pressure > 140 mmHg), diabetes, coronary artery disease,
tobacco use (in the past or current) and dyslipidemia were
recorded, as well as the medication of these patients.
Patients with atrial fibrillation, aortic valve disease,
mechanic heart valves, ipsilateral carotid artery occlusion
or restenosis after previous carotid endarterectomy were
excluded. Informed consent was given by each patient.
The study was approved by the local ethical committee.
The histological characteristics of symptomatic and
asymptomatic plaque samples have been published previ-
ously [17]. In short, carotid plaques from symptomatic
patients have shown lower levels of hydroxyapatite,
higher levels of elastin, cholesterol esters, unesterified
cholesterol, triglycerides, more cells, DNA, and soluble
protein [18] compared to those from asymptomatic
patients.
Sample Preparation
The plaques removed by endarterectomy were cleaned
with isotonic NaCl containing heparin (5 U/ml), to avoid
blood contamination, and thereafter the plaques were
immediately snap frozen in liquid nitrogen. Two-mm-
thick fragments from the stenotic region of the frozen
plaques were removed for histology. Plaques were
weighed, cut into pieces while still frozen, and homoge-
nized as previously described [19]. An aliquot was taken
from each plaque for western blot analysis, and protein
content was analyzed by the method of Lowry.
Immunoblotting and calpain activity
Loading buffer (final concentrations: 50 mmol/L Tris-HCl
[pH 6,8], 2% SDS, 10% glycerol, 0,1% bromophenol
blue, and 30 mmol/L dithiothreitol) was added to
homogenized samples, and they were heated to 90°C in a
heating block for 5 min. Proteins were separated under
reducing conditions in SDS-polyacrylamide gels and then
Western blotted onto PVDF filters. Blots were blocked
with Tris-buffered saline containing 5% dry milk powder,
and then incubated for 1–2 h with anti-proteolyzed 150
kDa  α-fodrin pAb [20](diluted 1:200), anti-α-tubulin
mAb (1:500), or anti-calpain-1 mAb (1:2000). The blots
were subsequently incubated with a peroxidase-conju-
gated secondary Ab, and bound Ab was assayed by
enhanced chemiluminescence detection (Santa Cruz Bio-
technology, Santa Cruz, CA). To estimate the level of cal-
pain activity, we performed densitometric analysis of
Western blots with a Fluor-S MultiImager (Bio-Rad, Rock-
ford, IL). The optical density of 150 kDa α-fodrin bands
and tubulin bands was scanned, and the calculated ratio
(ODα-fodrin/ODtubulin) for each plaque sample was used in
statistical analysis.
Immunohistochemistry
Two-millimeter-thick fragments from the stenotic regions
of the frozen plaques were embedded in O.C.T. com-
pound (Tissue-Tek, Sakura), cryo-sectioned in serial 8-μmBMC Cardiovascular Disorders 2009, 9:26 http://www.biomedcentral.com/1471-2261/9/26
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sections, and mounted on coated slides. Tissue sections
for immunohistochemistry were fixed with 4% parafor-
maldehyde in phosphate buffer. Membranes were perme-
abilized in 0.5% Triton X-100. Endogenous peroxidase
activity was quenched by incubating sections for 5 min in
0.9% H2O2. Thereafter sections were blocked with 10%
goat serum in PBS for 30 min. Primary antibody, rabbit
anti-cleaved-α-fodrin (150 kDa; ref. [20]), was diluted
1:200 and incubated overnight at 4°C in a humidified
chamber. Sections were incubated with biotinylated sec-
ondary Ab (goat anti-rabbit, Vector Laboratories, Burlin-
game, CA) at a dilution of 1:200 for 60 min. Thereafter,
sections were incubated with peroxidase- or alkaline
phosphatase-labeled Streptavidin (for brown or blue
stain, respectively; Vectastain ABC-AP kit, Vector Labora-
tories). In the case of double-staining, TUNEL was per-
formed after the anti-cleaved-α-fodrin staining. Sections
were developed with diaminobenzidine (Vector Laborato-
ries), and counterstained with hematoxylin. Negative con-
trols included substitution of the primary Ab with
phosphate buffer.
For TUNEL staining, consecutive tissue sections were fixed
with 4% paraformaldehyde in phosphate buffer and stained
for apoptosis, using TUNEL In Situ Cell Death detection kit
POD (Roche Applied Science, Indianapolis, USA), according
to the manufacturer's instructions. Samples were viewed
with an Olympus BX60 microscope and photographed.
Statistical Analysis
Results were normalized to the wet weight of the plaques.
We used χ2  analyses to investigate associations with
dichotomous variables. Two-group comparisons were
performed with the use of the Mann-Whitney non-para-
metric test. Spearman's rho was used for correlation anal-
yses. Statistical analysis was performed with the use of
SPSS 12.0 for Windows.
Results
Calpain activity and apoptosis
Use of Western blot analysis and a specific antibody to
detect a calpain-proteolyzed α-fodrin fragment has
proven to be one of the most reliable methods to demon-
strate calpain activation in cell lysates [6,20]. We
employed a polyclonal antibody specific for the calpain-
proteolyzed 150-kDa α-fodrin fragment [20] to determine
whether calpain activation occurs in atherosclerotic
plaques. We found that all plaque samples contained the
calpain-generated 150-kDa α-fodrin breakdown product
(Figure 1A). These results show that calpain was activated
and catalysed the cleavage of α-fodrin in the atheroscle-
rotic plaques.
The autoproteolytic cleavage of the 80 kDa subunit of cal-
pain-1 and -2 is known to be associated with activation of
these enzymes [3]. To further verify the activation of cal-
pain in atherosclerotic plaques, we used a monoclonal
antibody against the 80 kDa subunit of calpain-1 on west-
ern blots, and we observed the 78 kDa autoproteolysis
product of calpain-1 in all samples (Figure 1B). The detec-
tion of cleaved calpain-1 provided further evidence for
active calpain in atherosclerotic plaques.
The preparation of homogenates for western blot analysis
from plaque samples is a lengthy process, and despite the
included protease inhibitors it could be argued that the
proteolysis detected in Figure 1 might be artifacts from the
processing of the samples. Therefore we performed immu-
nohistochemistry on sections of the plaque samples, and
the results from this analysis verified that calpain was
indeed activated in the plaques. Figure 2 shows a plaque
with immunohistochemical staining of the calpain-gener-
ated 150-kDa α-fodrin fragment, as well as apoptotic cell
death detected by TUNEL staining. Interestingly, calpain
activity (Figure 2A, B, C, and 2D) colocalized with cell
death, as shown in Figure 2A, B, G, and 2H.
Calpain activity and plaque characteristics
When calpain activities were quantified from western
blots, we found that symptomatic carotid plaques dis-
Calpain-1 is activated in atherosclerotic plaques and cleaves  α-fodrin Figure 1
Calpain-1 is activated in atherosclerotic plaques and 
cleaves α-fodrin. A, Plaque homogenates were processed 
for Western blotting, and the PVDF membrane was probed 
with an anti-proteolyzed α-fodrin Ab specific for the 150-
kDa fragment produced by calpain activity. The membrane 
was subsequently stripped and re-probed with anti-α-tubulin 
Ab as a loading control. B, same as A, except that the PVDF 
membrane was probed with anti-calpain-1 large subunit Ab. 
The blots show 9 samples (the id number of each plaque is 
depicted above the lanes) of 29 analyzed. All 29 samples con-
tained the 150 kDa α-fodrin fragment as well as the autolytic 
fragment of calpain-1.BMC Cardiovascular Disorders 2009, 9:26 http://www.biomedcentral.com/1471-2261/9/26
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played significantly lower calpain activity (on average
38.0% less) compared with plaques not associated with
symptoms (Figure 3). Since calpain-dependent apoptosis
has been detected in simvastatin-treated rat vascular
smooth muscle cells [21], we decided to perform statisti-
cal analyses comparing calpain activity of the plaques and
statin intake. However, we found no significant difference
in calpain activity between untreated patients and those
taking statins (data not shown). There were no significant
differences in calpain activity between untreated patients
and those taking anti-hypertensives (including calcium-
channel blockers; Tables 1 and 2). Neither was there any
significant association found between calpain activity and
the registered cardiovascular risk factors.
Discussion
Our present data demonstrate unequivocally that calpain
was activated in atherosclerotic plaques and that calpain
activity was co-localized with cell death. Interestingly, in a
previous study on these carotid plaques, those associated
Immunohistochemical stainings of a human atherosclerotic  plaque Figure 2
Immunohistochemical stainings of a human athero-
sclerotic plaque. The region inside the square in A, C, E, 
and G is amplified in B, D, F, and H, respectively. A and B, 
sections were double stained for calpain (proteolyzed α-
fodrin, in blue) and TUNEL (in brown), showing colocaliza-
tion of these two stainings. The arrows in B show cells stain-
ing positively for calpain and TUNEL. C and D, sections were 
incubated with anti-proteolyzed α-fodrin antibody. α-fodrin 
fragments, resulting from the presence of active calpain, are 
present in the core and shoulder regions of the plaques and 
in some scattered areas of the fibrous cap. This is also seen 
in A with the blue colour. In D, cells stained brown are posi-
tive for calpain activity (long arrow), whereas non-stained 
cells (short arrow) are not. E and F, negative control (pri-
mary antibody omitted). G and H, TUNEL staining for cell 
death (in brown). The arrow in H points to a dying cell, stain-
ing brown.
Differences in calpain activity of carotid plaques from asymp- tomatic and symptomatic patients Figure 3
Differences in calpain activity of carotid plaques from 
asymptomatic and symptomatic patients. Calpain 
activity was estimated as described in Materials and Methods. 
The difference between asymptomatic and symptomatic 
plaques was statistically significant (p = 0.034). The box plot 
shows minimum, first quartile, median, third quartile, and 
maximum levels.
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Table 1: Most relevant clinical characteristics of the 
symptomatic patients.
Symptomatic (n = 12) No Yes
Diabetes 9 3
Hypertension 4 8
Heart disease 5 7
Smoking 4 current 3 and ex 5
Obesity 12 0
Family history of cardiovascular disease 11 1
Peripheral arterial disease 11 1
Statin 10 2
Anti-hypertensives 5 7 (3 CCB)
CCB, calcium channel blockersBMC Cardiovascular Disorders 2009, 9:26 http://www.biomedcentral.com/1471-2261/9/26
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with symptoms had 70% lower amounts of calcium
(hydroxyapatite) [19]. This is in accordance with other
studies suggesting that calcium could make plaques more
stable [22], limiting the spread of inflammation [14]. A
calcified nodule within or close to the plaque cap can pro-
trude and lead to rupture [23]. However, if the calcified
areas coalesce, the interfaces between rigid and distensible
areas as well as the mechanical stress decrease [14]. There-
fore, depending on their topography in the lesion, calci-
fied areas can function as a protective "shell".
The presence of bone proteins as well as bone and carti-
lage formation in calcified vascular lesions has suggested
that osteogenic mechanisms may play a role in vascular
calcification [24]. Interestingly, calpain-2 has been shown
to regulate matrix mineralization in a rat growth plate
chondrocyte culture model [25], suggesting that calpains
could be involved in vascular calcification. Furthermore, it
has been suggested that apoptotic bodies derived from
vascular smooth muscle cells may act as nucleating struc-
tures for calcium crystal formation and thus initiate vascu-
lar calcification [26]. A recent paper showed that vascular
smooth muscle cell apoptosis in transgenic mice induced
features of plaque vulnerability in atherosclerosis [27].
The fact that calpain regulates oxLDL-induced apoptosis
[12,28], and possibly other types of vascular cell death,
combined with the above-mentioned findings, suggests
that this enzyme may be a central regulator of vascular cal-
cification, and play an important role in the development
of vulnerable plaques.
Conclusion
Our results suggest that calpain-1 is commonly active in
carotid artery atherosclerotic plaques, and that calpain
activity is colocalized with cell death and inversely associ-
ated with symptoms.
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